Julie Rowe,
Anneliese Gonzalez,
Syed Jafri,
Putao Cen,
Zeyad Kanaan,
Robert Amato,
Adan Rios,
Hazem El Osta,
Virginia Mohlere
e.a.
McGraw-Hill Education
e druk, 2019
9781260026627
Hematology-Oncology Clinical Questions
Specificaties
Paperback, blz.
|
Engels
McGraw-Hill Education |
e druk, 2019
ISBN13: 9781260026627
Rubricering
Verwachte levertijd ongeveer 11 werkdagen
Samenvatting
Publisher's Note: Products purchased from Third Party sellers are not guaranteed by the publisher for quality, authenticity, or access to any online entitlements included with the product.
A unique point-of-care guide to clinical hematology-oncology that answers the most frequently asked questions
Hematology-Oncology Clinical Questions is the single-best resource for quickly converting the most current data and research into practical, diagnostic real-time solutions. This unique book answers more than 60 of the clinical hematology-oncology questions most commonly asked of the authors during consultation. The content flow simulates the consultation process: Question…Data…Synthesis…Solution.
The initial chapters prepare you with essential background fundamentals of hematology-oncology. Subsequent chapters are divided into tumor type, beginning with solid tumor types, and then hematological malignancies. Each chapter includes:
• Key Concepts
• The Clinical Scenario
• The Action Items
• Pearls
Hematology-Oncology Clinical Questions will prove to be a powerful tool to help learners from all points of the clinical spectrum understand the basic concepts of caring for a cancer patient.
Specificaties
Inhoudsopgave
<p><B><span>Table of Contents</SPAN></B></P><p><B></B> </P><p><B></B></P><p><span><SPAN>1.<span> </SPAN></SPAN></SPAN><span>CHEMOTHERAPY AGENTS –WILL INCLUDE A SUMMARY OF EACH TYPE BEFORE CLINICAL QUESTIONS</SPAN></P><p></P><p><span><SPAN>a.<span> </SPAN></SPAN></SPAN><span>Cytotoxic</SPAN></P><p><span><SPAN>b.<span> </SPAN></SPAN></SPAN><span>Targeted Agents </SPAN></P><p><span><SPAN>c.<span> </SPAN></SPAN></SPAN><span>Hormonal Agents</SPAN></P><p><span><SPAN>d.<span> </SPAN></SPAN></SPAN><span>Immunotherapy</SPAN></P><p></P><p><span><SPAN>2.<span> </SPAN></SPAN></SPAN><span>RADIATION THERAPY</SPAN></P><p></P><p><span><SPAN>3.<span> </SPAN></SPAN></SPAN><span>MOST COMMON HEME QUESTIONS</SPAN></P><p><span><SPAN>a.<span> </SPAN></SPAN></SPAN><span>Anemia</SPAN></P><p><span><SPAN>b.<span> </SPAN></SPAN></SPAN><span>Thrombocytopenia</SPAN></P><p><span><SPAN>c.<span> </SPAN></SPAN></SPAN><span>Thrombosis</SPAN></P><p><span><SPAN>d.<span> </SPAN></SPAN></SPAN><span>Transfusion reactions</SPAN></P><p></P><p><span><SPAN>4.<span> </SPAN></SPAN></SPAN><span>SCREENING </SPAN></P><p><span><SPAN>a.<span> </SPAN></SPAN></SPAN><span>Breast cancer </SPAN></P><p><span><SPAN>b.<span> </SPAN></SPAN></SPAN><span>Cervical </SPAN></P><p><span><SPAN>c.<span> </SPAN></SPAN></SPAN><span>Colon Cancer </SPAN></P><p><span><SPAN>d.<span> </SPAN></SPAN></SPAN><span>Prostate </SPAN></P><p><span><SPAN>e.<span> </SPAN></SPAN></SPAN><span>Lung Cancer </SPAN></P><p></P><p><span><SPAN>5.<span> </SPAN></SPAN></SPAN><span>BREAST CANCER </SPAN></P><p><span><SPAN>a.<span> </SPAN></SPAN></SPAN><span>Non-invasive </SPAN></P><p><span><SPAN>b.<span> </SPAN></SPAN></SPAN><span>Invasive </SPAN></P><p><span><SPAN>c.<span> </SPAN></SPAN></SPAN><span>Inflammatory breast cancer </SPAN></P><p><span><SPAN>d.<span> </SPAN></SPAN></SPAN><span>Phyllodes </SPAN></P><p><span><SPAN>e.<span> </SPAN></SPAN></SPAN><span>Paget’s </SPAN></P><p></P><p><span><SPAN>6.<span> </SPAN></SPAN></SPAN><span>HEAD AND NECK </SPAN></P><p></P><p><span><SPAN>7.<span> </SPAN></SPAN></SPAN><span>THYROID CARCINOMAS </SPAN></P><p></P><p><span><SPAN>8.<span> </SPAN></SPAN></SPAN><span>GI CANCER </SPAN></P><p><span><SPAN>a.<span> </SPAN></SPAN></SPAN><span>Esophagus </SPAN></P><p><span><SPAN>b.<span> </SPAN></SPAN></SPAN><span>Gastric/GEJ </SPAN></P><p><span><SPAN>c.<span> </SPAN></SPAN></SPAN><span>Colon </SPAN></P><p><span><SPAN>d.<span> </SPAN></SPAN></SPAN><span>Rectal </SPAN></P><p><span><SPAN>e.<span> </SPAN></SPAN></SPAN><span>Anus </SPAN></P><p><span><SPAN>f.<span> </SPAN></SPAN></SPAN><span>Pancreas </SPAN></P><p><span><SPAN>g.<span> </SPAN></SPAN></SPAN><span>Cholangiocarcinoma </SPAN></P><p><span><SPAN>h.<span> </SPAN></SPAN></SPAN><span>Hepatocellular Carcinoma </SPAN></P><p><span><SPAN>i.<span> </SPAN></SPAN></SPAN><span>Neuroendocrine tumors </SPAN></P><p></P><p><span><SPAN>9.<span> </SPAN></SPAN></SPAN><span>GU CANCER </SPAN></P><p><span><SPAN>a.<span> </SPAN></SPAN></SPAN><span>Bladder </SPAN></P><p><span><SPAN>b.<span> </SPAN></SPAN></SPAN><span>Kidney </SPAN></P><p><span><SPAN>c.<span> </SPAN></SPAN></SPAN><span>Prostate </SPAN></P><p><span><SPAN>d.<span> </SPAN></SPAN></SPAN><span>Testicular </SPAN></P><p></P><p><span><SPAN>10.<span> </SPAN></SPAN></SPAN><span>GYNECOLOGICAL MALIGNANCIES </SPAN></P><p><span><SPAN>a.<span> </SPAN></SPAN></SPAN><span>Cervical </SPAN></P><p><span><SPAN>b.<span> </SPAN></SPAN></SPAN><span>Endometrial</SPAN></P><p><span><SPAN>c.<span> </SPAN></SPAN></SPAN><span>Ovarian </SPAN></P><p><span><SPAN>d.<span> </SPAN></SPAN></SPAN><span>Uterine </SPAN></P><p></P><p><span><SPAN>11.<span> </SPAN></SPAN></SPAN><span>MELANOMAS </SPAN></P><p></P><p><span><SPAN>12.<span> </SPAN></SPAN></SPAN><span>THORACIC </SPAN></P><p><span><SPAN>a.<span> </SPAN></SPAN></SPAN><span>Small cell lung cancer </SPAN></P><p><span><SPAN>b.<span> </SPAN></SPAN></SPAN><span>Non-small cell lung cancer </SPAN></P><p></P><p><span><SPAN>13.<span> </SPAN></SPAN></SPAN><span>SARCOMAS </SPAN></P><p></P><p><span><SPAN>14.<span> </SPAN></SPAN></SPAN><span>OCCULT PRIMARY </SPAN></P><p></P><p><span><SPAN>15.<span> </SPAN></SPAN></SPAN><span>BASICS OF PATHOLOGY AND HEMATOLOGY</SPAN></P><p><span><SPAN>a.<span> </SPAN></SPAN></SPAN><span>Bone Marrow, Flow Cytometry, Cytogenetics, Molecular testing.</SPAN></P><p><span><SPAN>b.<span> </SPAN></SPAN></SPAN><span>Solid tumor pathology basics</SPAN></P><p></P><p><span><SPAN>16.<span> </SPAN></SPAN></SPAN><span>BASICS OF BONE MARROW TRANSPLANTATION</SPAN></P><p><span><SPAN>a.<span> </SPAN></SPAN></SPAN><span>Types (Allo, Auto)</SPAN></P><p><span><SPAN>b.<span> </SPAN></SPAN></SPAN><span>Indications</SPAN></P><p></P><p><span><SPAN>17.<span> </SPAN></SPAN></SPAN><span>LYMPHOMAS </SPAN></P><p><span><SPAN>a.<span> </SPAN></SPAN></SPAN><span>Hodgkin’s Lymphoma </SPAN></P><p><span><SPAN>i.<span> </SPAN></SPAN></SPAN><span>Classical HL</SPAN></P><p><span><SPAN>ii.<span> </SPAN></SPAN></SPAN><span>Nodular lymphocyte-predominant HL</SPAN></P><p><span><SPAN>b.<span> </SPAN></SPAN></SPAN><span>Non-Hodgkin’s Lymphoma </SPAN></P><p><span><SPAN>i.<span> </SPAN></SPAN></SPAN><span>B-cell NHL</SPAN></P><p><span><SPAN>a)<span> </SPAN></SPAN></SPAN><span>Diffuse large B-cell Lymphoma (DLBCL)</SPAN></P><p><span><SPAN>b)<span> </SPAN></SPAN></SPAN><span>Follicular Lymphoma</SPAN></P><p><span><SPAN>c)<span> </SPAN></SPAN></SPAN><span>Mantle Cell Lymphoma (MCL)</SPAN></P><p><span><SPAN>d)<span> </SPAN></SPAN></SPAN><span>Small Lymphocytic Lymphoma (SLL)</SPAN></P><p><span><SPAN>e)<span> </SPAN></SPAN></SPAN><span>Primary CNS Lymphoma</SPAN></P><p><span><SPAN>f)<span> </SPAN></SPAN></SPAN><span>Primary Mediastinal Lymphoma (PML)</SPAN></P><p><span><SPAN>g)<span> </SPAN></SPAN></SPAN><span>Burkitt Lymphoma (BL)</SPAN></P><p><span><SPAN>h)<span> </SPAN></SPAN></SPAN><span>Primary Effusion Lymphoma</SPAN></P><p><span><SPAN>i)<span> </SPAN></SPAN></SPAN><span>Double-hit Lymphoma</SPAN></P><p><span><SPAN>j)<span> </SPAN></SPAN></SPAN><span>Primary Effusion Lymphoma (PEL)</SPAN></P><p><span><SPAN>ii.<span> </SPAN></SPAN></SPAN><span>T-Cell NHL</SPAN></P><p><span><SPAN>a)<span> </SPAN></SPAN></SPAN><span>Peripheral T-cell Lymphoma (PTCL)</SPAN></P><p><span><SPAN>b)<span> </SPAN></SPAN></SPAN><span>Primary Cutaneous T-cell Lymphoma</SPAN></P><p><span><SPAN>c)<span> </SPAN></SPAN></SPAN><span>Anaplastic Large Cell Lymphoma (ALCL)</SPAN></P><p><span><SPAN>d)<span> </SPAN></SPAN></SPAN><span>Post-Transplant Lymphoproliferative </SPAN></P><p></P><p><span><SPAN>18.<span> </SPAN></SPAN></SPAN><span>LEUKEMIAS </SPAN></P><p><span><SPAN>a)<span> </SPAN></SPAN></SPAN><span>Acute Leukemias</SPAN></P><p><span><SPAN>i.<span> </SPAN></SPAN></SPAN><span>Acute Myeloid Leukemia (AML)</SPAN></P><p><span><SPAN>ii.<span> </SPAN></SPAN></SPAN><span>APL</SPAN></P><p><span><SPAN>i.<span> </SPAN></SPAN></SPAN><span>Acute Lymphoblastic Leukemia (ALL) </SPAN></P><p><span><SPAN>b)<span> </SPAN></SPAN></SPAN><span>Chronic Leukemias:</SPAN></P><p><span><SPAN>i.<span> </SPAN></SPAN></SPAN><span>Chronic Myeloid Leukemia (CML)</SPAN></P><p><span><SPAN>ii.<span> </SPAN></SPAN></SPAN><span>Chronic Lymphocytic Leukemia (CLL)</SPAN></P><p><span><SPAN>iii.<span> </SPAN></SPAN></SPAN><span>Hairy Cell Leukemia</SPAN></P><p></P><p><span><SPAN>19.<span> </SPAN></SPAN></SPAN><span>PLASMA CELL DISORDERS:</SPAN></P><p><span><SPAN>a.<span> </SPAN></SPAN></SPAN><span>Monoclonal Gammopathy of Undetermined Significance (MGUS)</SPAN></P><p><span><SPAN>b.<span> </SPAN></SPAN></SPAN><span>Multiple Myeloma (MM)</SPAN></P><p><span><SPAN>c.<span> </SPAN></SPAN></SPAN><span>Lymphoplasmacyctic Lymphoma (including Waldenstrom’s Macroglobulinemia)</SPAN></P><p><span><SPAN>d.<span> </SPAN></SPAN></SPAN><span>Solitary Plasmacytoma</SPAN></P><p><span><SPAN>e.<span> </SPAN></SPAN></SPAN><span>AL Amyloidosis</SPAN></P><p><span><SPAN>f.<span> </SPAN></SPAN></SPAN><span>POEMS Syndrome</SPAN></P><p></P><p><span><SPAN>20.<span> </SPAN></SPAN></SPAN><span>MYELOPROLIFERATIVE NEOPLASMS </SPAN></P><p><span><SPAN>a.<span> </SPAN></SPAN></SPAN><span>Polycythemia Vera (PV)</SPAN></P><p><span><SPAN>b.<span> </SPAN></SPAN></SPAN><span>Essential Thrombocythemia (ET)</SPAN></P><p><span><SPAN>c.<span> </SPAN></SPAN></SPAN><span>Primary Myelofibrosis (PMF)</SPAN></P><p><span><SPAN>d.<span> </SPAN></SPAN></SPAN><span>Systemic Mastocytosis (SM)</SPAN></P><p></P><p><span><SPAN>21.<span> </SPAN></SPAN></SPAN><span>MYELODYSPLASTIC SYNDROMES </SPAN></P><p></P><p><span><SPAN>22.<span> </SPAN></SPAN></SPAN><span>GUIDELINES FOR SUPPORTIVE CARE </SPAN></P><p><span><SPAN>a.<span> </SPAN></SPAN></SPAN><span>Management of Side Effects of Chemotherapy</SPAN></P><p><span><SPAN>i.<span> </SPAN></SPAN></SPAN><span>Myelosuppression </SPAN></P><p><span><SPAN>ii.<span> </SPAN></SPAN></SPAN><span>Nausea</SPAN></P><p><span><SPAN>iii.<span> </SPAN></SPAN></SPAN><span>Vomiting</SPAN></P><p><span><SPAN>iv.<span> </SPAN></SPAN></SPAN><span>Diarrhea</SPAN></P><p><span><SPAN>v.<span> </SPAN></SPAN></SPAN><span>Mucositis</SPAN></P><p><span><SPAN>vi.<span> </SPAN></SPAN></SPAN><span>Anorexia, weight loss</SPAN></P><p><span><SPAN>b.<span> </SPAN></SPAN></SPAN><span>Management of Cancer-related pain </SPAN></P><p><span><SPAN>c.<span> </SPAN></SPAN></SPAN><span>Management of Cachexia </SPAN></P><p></P><p><span><SPAN>23.<span> </SPAN></SPAN></SPAN><span>ONCOLOGIC EMERGENCIES </SPAN></P><p><span><SPAN>a.<span> </SPAN></SPAN></SPAN><span>Neutropenic Fever </SPAN></P><p><span><SPAN>b.<span> </SPAN></SPAN></SPAN><span>Spinal Cord Compression</SPAN></P><p><span><SPAN>c.<span> </SPAN></SPAN></SPAN><span>Tumor Lysis Syndrome </SPAN></P><p><span><SPAN>d.<span> </SPAN></SPAN></SPAN><span>Superior vena cava syndrome </SPAN></P><p><span><SPAN>e.<span> </SPAN></SPAN></SPAN><span>Hypercalcemia of malignancy </SPAN></P><p><span><SPAN>f.<span> </SPAN></SPAN></SPAN><span>Hyperleukocytosis and leukostasis</SPAN></P><p></P><p><span><SPAN>24.<span> </SPAN></SPAN></SPAN><span>GENETIC AND FAMILIAL ASSESSMENT
FOR FAMILIAL CANCER SYNDROMES</SPAN></P><p></P><p><span><SPAN>25.<span> </SPAN></SPAN></SPAN><span>END OF LIFE </SPAN></P><p></P>
FOR FAMILIAL CANCER SYNDROMES</SPAN></P><p></P><p><span><SPAN>25.<span> </SPAN></SPAN></SPAN><span>END OF LIFE </SPAN></P><p></P>